DMYD B — Diamyd Medical AB Share Price
Last trade - 00:00- SEK1.13bn
- SEK1.02bn
- SEK0.55m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 6.23 | ||
| Price to Tang. Book | 6.23 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 4,006.67 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -60.38% | ||
| Return on Equity | -71.18% | ||
| Operating Margin | -44095.39% | ||
Financial Summary
| Year End 31st Aug | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | SEKm | 1.57 | 0.34 | 0.25 | 0.45 | 0.55 | 1 | 1 | -5.54% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | +512.9 | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Diamyd Medical AB is a Sweden-based diabetes company. It is active in the field of pharmaceutical development and investments in stem cell and medical technology. The Company develops the diabetes vaccine, Diamyd, with the active glutamic acid decarboxylase (GAD) ingredient for the treatment and prevention of autoimmune diabetes. The vaccine is intended for the treatment of children and adolescents with recent-onset type one diabetes, as well as those at high risk of developing the disease.
Directors
- Erik Nerpin NEC (60)
- Ulf Hannelius CEO (46)
- Anna Styrud CFO (60)
- Anton Lindqvist CSO (41)
- Maja Johansson OTH (59)
- Eva Karlstrom OTH (57)
- Martina Widman OTH (40)
- Maria-Teresa Essen-moeller DRC (51)
- Mark Atkinson IND (60)
- Torbjoern Baeckstroem IND (73)
- Anders Essen-moeller IND (80)
- Karin Hehenberger IND (49)
- Last Annual
- August 31st, 2023
- Last Interim
- February 29th, 2024
- Incorporated
- March 27th, 1984
- Public Since
- May 20th, 2013
- No. of Shareholders
- 16,001
- No. of Employees
- 26
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- OMX Nordic Exchange Stockholm
- Shares in Issue
- 94,947,996
- Address
- Kungsgatan 29, STOCKHOLM, 111 56
- Web
- https://www.diamyd.com/
- Phone
- +46 86610026
- Contact
- Ulf Hannelius
- Auditors
- BDO Malardalen AB
Upcoming Events for DMYD B
Similar to DMYD B
2cureX AB
OMX Nordic Exchange Stockholm
Abliva AB
OMX Nordic Exchange Stockholm
Acousort AB
OMX Nordic Exchange Stockholm
Active Biotech AB publ
OMX Nordic Exchange Stockholm
AddLife AB
OMX Nordic Exchange Stockholm
FAQ
As of Today at 19:06 UTC, shares in Diamyd Medical AB are trading at SEK11.90. This share price information is delayed by 15 minutes.
Shares in Diamyd Medical AB last closed at SEK11.90 and the price had moved by -36.98% over the past 365 days. In terms of relative price strength the Diamyd Medical AB share price has underperformed the FTSE Global All Cap Index by -42.27% over the past year.
The overall consensus recommendation for Diamyd Medical AB is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Diamyd Medical AB does not currently pay a dividend.
Diamyd Medical AB does not currently pay a dividend.
Diamyd Medical AB does not currently pay a dividend.
To buy shares in Diamyd Medical AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of SEK11.90, shares in Diamyd Medical AB had a market capitalisation of SEK1.13bn.
Here are the trading details for Diamyd Medical AB:
- Country of listing: Sweden
- Exchange: STO
- Ticker Symbol: DMYD B
Based on an overall assessment of its quality, value and momentum Diamyd Medical AB is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Diamyd Medical AB. Over the past six months, its share price has outperformed the FTSE Global All Cap Index by +47.18%.
As of the last closing price of SEK11.90, shares in Diamyd Medical AB were trading +29.18% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Diamyd Medical AB PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at SEK11.90.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Diamyd Medical AB's management team is headed by:
- Erik Nerpin - NEC
- Ulf Hannelius - CEO
- Anna Styrud - CFO
- Anton Lindqvist - CSO
- Maja Johansson - OTH
- Eva Karlstrom - OTH
- Martina Widman - OTH
- Maria-Teresa Essen-moeller - DRC
- Mark Atkinson - IND
- Torbjoern Baeckstroem - IND
- Anders Essen-moeller - IND
- Karin Hehenberger - IND